Drug-Coated Balloons in Coronary Interventions: Invited Lecture at CVI Denver 2024

Dr. Michael Megaly shares insights from his invited faculty presentation at Cardiovascular Innovations 2024 on the evolving role of drug-coated balloons as an alternative to stenting in selected coronary lesions.

Invited Faculty at One of Interventional Cardiology's Premier Annual Conferences

In July 2024

Dr. Michael Megaly served as invited faculty at the Cardiovascular Innovations (CVI) conference in Denver, Colorado, one of the most respected annual meetings in interventional cardiology, known for its focus on emerging technologies and real-world techniques.

His lecture addressed a question that has generated significant interest across the field: What is the future of drug-coated balloons (DCBs) in coronary interventions?

Why Drug-Coated Balloons Matter Now

For decades, coronary artery disease has been treated with stents, metal scaffolds that hold open narrowed arteries and deliver medication locally to prevent re-narrowing. Drug-eluting stents transformed outcomes for millions of patients and remain the standard of care for most lesions. But stents are permanent implants, and in certain clinical scenarios, leaving metal behind creates real problems: ongoing inflammation, the need for prolonged dual antiplatelet therapy, restricted future surgical options, and the compounding challenge of managing in-stent restenosis over time.

Drug-coated balloons offer a fundamentally different approach. A DCB delivers an antiproliferative drug directly to the vessel wall during balloon inflation, without leaving a permanent implant. The concept is straightforward: treat the diseased segment, restore flow, and leave no metal behind.

What the Evidence Shows — and Where It's Going

DCBs are being investigated in multiple areas: in-stent restenosis (ISR), small-vessel coronary artery disease, bifurcation disease, and in diabetic patients. In ISR, DCBs are guideline-supported and widely used. In small vessels, typically < 2.5-2.75mm in diameter, the data increasingly support DCBs as a legitimate alternative to stenting, with comparable outcomes and the meaningful advantage of no permanent implant.

What is now evolving is the expansion of DCB use into larger vessels and more complex lesion subsets: bifurcations, de novo lesions in selected patients, and high-bleeding-risk populations where shorter antiplatelet duration is a priority.

Dr. Megaly's lecture at CVI 2024 reviewed the current evidence base, outlined patient and lesion selection criteria, and addressed where DCBs fit within a modern interventional strategy, and where the data do not yet support replacing stenting.

The field is moving quickly. Several ongoing randomized trials are examining DCBs in large-vessel de novo disease, and results over the next several years will determine whether DCBs become a mainstream first-line option beyond their current indications. Dr. Megaly's own research includes published work on drug-coated balloons in small-vessel coronary artery disease and in-stent restenosis, informing both his lecture content and his clinical approach.

What This Means for Patients in Oklahoma and the Region

For patients in Oklahoma and surrounding states, access to a physician who follows this evidence closely and applies it with precision matters. Not every lesion is suited for a DCB, and not every operator offering DCBs has the experience to select cases correctly or navigate the technical demands of the procedure. The decision between a DCB and a stent is not a preference; it is a clinical judgment that must be individualized to the patient's anatomy, comorbidities, antiplatelet tolerance, and long-term goals.

Drug-coated balloon therapy for appropriate coronary indications is available in the region as part of a comprehensive, evidence-based approach to complex coronary intervention, offering patients with in-stent restenosis, small-vessel disease, or high bleeding risk access to this emerging technology closer to home.

Dr. Michael Megaly specializes in complex and high-risk coronary interventions, chronic total occlusion (CTO) PCI, surgical turn-downs, complex peripheral artery disease, and limb salvage at Integris Health Heart Hospital in Oklahoma City